- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 495/08 - Bridged systems
Patent holdings for IPC class C07D 495/08
Total number of patents in this class: 85
10-year publication summary
|
11
|
2
|
9
|
6
|
10
|
2
|
3
|
2
|
5
|
0
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Merck Sharp & Dohme LLC | 3752 |
7 |
| Genentech, Inc. | 3874 |
5 |
| Universitat Rovira I Virgili | 102 |
4 |
| Bristol-myers Squibb Company | 4865 |
3 |
| Georgia Tech Research Corporation | 2617 |
3 |
| Alnylam Pharmaceuticals, Inc. | 1137 |
3 |
| Fundació Institut Català D'investigació Química (iciq) | 47 |
3 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2842 |
3 |
| Sanofi | 3957 |
3 |
| Merck Sharp & Dohme Corp. | 2217 |
2 |
| Merck Patent GmbH | 5848 |
2 |
| Astellas Pharma Inc. | 1126 |
2 |
| The Global Alliance for TB Drug Development, Inc. | 44 |
2 |
| Schering Corporation | 502 |
2 |
| Tokyo Ohka Kogyo Co., Ltd. | 1504 |
2 |
| USA Elixiria Biotech Inc | 3 |
2 |
| Samsung Display Co., Ltd. | 32868 |
1 |
| LG Chem, Ltd. | 17643 |
1 |
| Janssen Pharmaceutica N.V. | 3611 |
1 |
| California Institute of Technology | 3935 |
1 |
| Other owners | 33 |